T. G. Roberts, T. J. Lynch, and B. A. Chabner, The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision, J Clin Oncol, vol.21, pp.3683-95, 2003.

B. R. Hirsch, R. M. Califf, and S. K. Cheng, Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov, JAMA Intern Med, vol.173, pp.972-981, 2013.

I. Walker and H. Newell, Do molecularly targeted agents in oncology have reduced attrition rates?, Nat Rev Drug Discov, vol.8, pp.15-21, 2009.

M. I. Zia, L. L. Siu, G. R. Pond, and E. X. Chen, Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens, J Clin Oncol, vol.23, pp.6982-91, 2005.

L. Seymour, S. P. Ivy, and D. Sargent, The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee, Clin Cancer Res, vol.16, pp.1764-1773, 2010.

T. Grellety, A. Petit-monéger, and A. Diallo, Quality of reporting of phase II trials: a focus on highly ranked oncology journals, Ann Oncol, vol.25, pp.536-577, 2014.

E. S. Kim, D. Bernstein, S. G. Hilsenbeck, C. H. Chung, A. P. Dicker et al., Modernizing Eligibility Criteria for Molecularly Driven Trials, J Clin Oncol, vol.33, pp.2815-2835, 2015.

N. Penel, S. Clisant, and J. L. Lefebvre, Sufficient life expectancy": an amazing inclusion criterion in cancer phase II-III trials, J Clin Oncol, vol.27, p.105, 2009.

Z. A. Nurgat, W. Craig, and N. C. Campbell, Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy, Br J Cancer, vol.92, pp.1001-1006, 2005.

P. A. Harris, R. Taylor, and R. Thielke, Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform, vol.42, pp.377-81, 2009.

H. T. Arkenau, D. Olmos, and J. E. Ang, Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience, Br J Cancer, vol.98, pp.1029-1062, 2008.

N. G. Chau, A. Florescu, and K. K. Chan, Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?, BMC Cancer, vol.11, p.426, 2011.

M. Schwaederle, M. Zhao, and J. J. Lee, Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials, J Clin Oncol, vol.33, pp.3817-3842, 2015.

D. W. Hosmer and S. Lemeshow, A goodness-of-fit test for the multiple logistic regression model, Commun Stat, vol.10, pp.1043-69, 1980.

T. Bachelot, I. Ray-coquard, and G. Catimel, Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials, Ann Oncol, vol.11, pp.151-157, 2000.

C. Stavraka, D. J. Pinato, and S. J. Turnbull, Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials, Cancer, vol.120, pp.262-70, 2014.

H. Ludwig, S. Van-belle, and P. Barrett-lee, The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients, Eur J Cancer, vol.40, pp.2293-306, 2004.

J. J. Caro, M. Salas, and A. Ward, Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review, Cancer, vol.91, pp.2214-2235, 2001.

M. H. Yang, M. Z. Wu, and S. H. Chiou, Direct regulation of TWIST by HIF-1 alpha promotes metastasis, Nat Cell Biol, vol.10, pp.295-305, 2008.

M. Z. Qiu, R. H. Xu, and D. Y. Ruan, Incidence of anemia, leukocytosis, and thrombocytosis in patients with solid tumors in China, Tumour Biol, vol.31, pp.633-674, 2010.

R. Banerjee, G. Roxin, and M. Eliasziw, The prognostic significance of pretreatment leukocytosis in patients with anal cancer treated with radical chemoradiotherapy or radiotherapy, Dis Colon Rectum, vol.56, pp.1036-1078, 2013.

C. M. Coppin, M. K. Gospodarowicz, and K. James, Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, vol.14, pp.2901-2908, 1996.

I. Kasuga, S. Makino, and H. Kiyokawa, Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma, Cancer, vol.92, pp.2399-405, 2001.

C. H. Köhne, D. Cunningham, D. Costanzo, and F. , Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients, Ann Oncol, vol.13, pp.308-325, 2002.

P. Maione, A. Rossi, D. Maio, and M. , Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer? Lung Cancer, vol.66, pp.8-14, 2009.

K. A. So, J. H. Hong, and H. M. Jin, The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study, Gynecol Oncol, vol.132, pp.551-556, 2014.

M. J. Worley, C. C. Nitschmann, and M. Shoni, Preoperative leukocytosis imposes an increased risk of recurrence and death among patients with nonendometrioid endometrial carcinoma, Int J Gynecol Cancer, vol.23, pp.312-319, 2013.

Y. Chen, C. Lin, and I. , Prognostic value of hypercalcaemia and leucocytosis in resected oral squamous cell carcinoma, Br J Oral Maxillofac Surg, vol.52, pp.425-456, 2014.

J. M. Granger and D. P. Kontoyiannis, Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients, Cancer, vol.115, pp.3919-3942, 2009.

J. Cerny and A. G. Rosmarin, Why does my patient have leukocytosis?, Hematol Oncol Clin North Am, vol.26, pp.303-322, 2012.